Healthcare -
Biotechnology - NASDAQ - US
$ 5.01
5.92 %
$ 322 M
Market Cap
-5.06
P/E
1. INTRINSIC VALUE
Balance Sheet
Corvus Pharmaceuticals, Inc.
| Current Assets | 28 M |
| Cash & Short-Term Investments | 27.1 M |
| Receivables | 63 K |
| Other Current Assets | 744 K |
| Non-Current Assets | 17.6 M |
| Long-Term Investments | 16.1 M |
| PP&E | 1.38 M |
| Other Non-Current Assets | 89 K |
| Current Liabilities | 6.87 M |
| Accounts Payable | 1.52 M |
| Short-Term Debt | 1.37 M |
| Other Current Liabilities | 3.97 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Corvus Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 151 K |
| Gross Profit | -151 K |
| Operating Expenses | 23.3 M |
| Operating Income | -23.4 M |
| Other Expenses | 3.62 M |
| Net Income | -27 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Corvus Pharmaceuticals, Inc.
| Net Income | -27 M |
| Depreciation & Amortization | 151 K |
| Capital Expenditures | -34 K |
| Stock-Based Compensation | 2.15 M |
| Change in Working Capital | -3.59 M |
| Others | 685 K |
| Free Cash Flow | -24 M |
Wall Street Analysts Price Targets
Corvus Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for CRVS of $11.4 , with forecasts ranging from
a
low of
$7 to a high of $13 .
CRVS Lowest Price Target
Wall Street Target
7 USD
39.72%
CRVS Average Price Target
Wall Street Target
11.4 USD
127.54%
CRVS Highest Price Target
Wall Street Target
13 USD
159.48%
4. DIVIDEND
ANALYSIS
CRVS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Corvus Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
12.8 M USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
8 months ago
May 06, 2024
|
Bought
144 USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 1444085
|
0.0001 USD |
|
8 months ago
May 06, 2024
|
Bought
4.89 M USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 1397684
|
3.5 USD |
|
8 months ago
May 06, 2024
|
Bought
144 USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 1444085
|
0.0001 USD |
|
8 months ago
May 06, 2024
|
Bought
4.89 M USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 1397684
|
3.5 USD |
|
8 months ago
May 06, 2024
|
Bought
34.6 K USD
|
Jones William Benton
See Remarks
|
+ 20000
|
1.7312 USD |
|
8 months ago
May 06, 2024
|
Bought
67.7 K USD
|
Jones William Benton
See Remarks
|
+ 19357
|
3.5 USD |
|
8 months ago
May 06, 2024
|
Bought
1 M USD
|
MILLER RICHARD A MD
President and CEO
|
+ 577634
|
1.7312 USD |
|
8 months ago
May 06, 2024
|
Bought
1.96 M USD
|
MILLER RICHARD A MD
President and CEO
|
+ 559073
|
3.5 USD |
|
1 year ago
May 15, 2023
|
Bought
24.5 K USD
|
Grais Linda
Director
|
+ 10000
|
2.45 USD |
|
2 years ago
Dec 20, 2022
|
Bought
15.8 K USD
|
Jones William Benton
See Remarks
|
+ 20000
|
0.79 USD |
|
2 years ago
Dec 14, 2022
|
Bought
3.36 K USD
|
LEA LEIV
Chief Financial Officer
|
+ 4000
|
0.841 USD |
|
2 years ago
Dec 13, 2022
|
Bought
22.3 K USD
|
LEA LEIV
Chief Financial Officer
|
+ 30000
|
0.7425 USD |
|
2 years ago
Dec 14, 2022
|
Bought
7.81 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 10000
|
0.7812 USD |
|
2 years ago
Dec 13, 2022
|
Bought
37 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 50000
|
0.7403 USD |
|
2 years ago
Sep 28, 2022
|
Bought
19.1 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 25000
|
0.7628 USD |
|
2 years ago
Sep 20, 2022
|
Bought
4.07 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
0.815 USD |
|
2 years ago
Sep 20, 2022
|
Bought
2.21 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 2700
|
0.82 USD |
|
2 years ago
Sep 20, 2022
|
Bought
9.96 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 12300
|
0.8101 USD |
|
2 years ago
Jun 24, 2022
|
Bought
4.98 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
0.9969 USD |
|
2 years ago
Jun 24, 2022
|
Bought
5.15 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
1.03 USD |
|
2 years ago
Jun 02, 2022
|
Bought
899 USD
|
MILLER RICHARD A MD
President and CEO
|
+ 890
|
1.01 USD |
|
2 years ago
Jun 02, 2022
|
Bought
165 USD
|
MILLER RICHARD A MD
President and CEO
|
+ 170
|
0.97 USD |
|
2 years ago
Jun 02, 2022
|
Bought
4.73 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 4830
|
0.98 USD |
|
2 years ago
Mar 31, 2022
|
Bought
24.5 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 15000
|
1.6356 USD |
|
2 years ago
Mar 16, 2022
|
Bought
22.9 K USD
|
LEA LEIV
Chief Financial Officer
|
+ 13878
|
1.65 USD |
|
2 years ago
Mar 15, 2022
|
Bought
7.95 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
1.59 USD |
|
2 years ago
Mar 15, 2022
|
Bought
36.6 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 25000
|
1.466 USD |
|
3 years ago
Sep 30, 2021
|
Sell 15.1 M
USD
|
EcoR1 Capital, LLC
10 percent owner
|
- 3000000
|
5.0437 USD |
|
3 years ago
Oct 01, 2021
|
Sell 9.93 M
USD
|
EcoR1 Capital, LLC
10 percent owner
|
- 2000000
|
4.9644 USD |
|
3 years ago
Sep 20, 2021
|
Sell 6.76 M
USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
- 1109644
|
6.09 USD |
|
3 years ago
Sep 20, 2021
|
Sell 6.76 M
USD
|
Thompson Peter A.
director, 10 percent owner:
|
- 1109644
|
6.09 USD |
|
3 years ago
Aug 20, 2021
|
Bought
19.3 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 10000
|
1.9254 USD |
|
3 years ago
May 04, 2021
|
Bought
100 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 35714
|
2.8 USD |
|
3 years ago
Feb 17, 2021
|
Bought
4.5 M USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 1285714
|
3.5 USD |
|
3 years ago
Feb 17, 2021
|
Bought
4.5 M USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 1285714
|
3.5 USD |
|
3 years ago
Feb 17, 2021
|
Bought
350 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 100000
|
3.5 USD |
|
4 years ago
Jul 07, 2020
|
Sell 4.18 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 796622
|
5.2514 USD |
|
4 years ago
Jul 08, 2020
|
Sell 3.99 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 741440
|
5.3749 USD |
|
5 years ago
Nov 13, 2019
|
Bought
44.2 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 14736
|
3.0022 USD |
|
5 years ago
Nov 12, 2019
|
Bought
789 USD
|
MILLER RICHARD A MD
President and CEO
|
+ 272
|
2.9 USD |
|
5 years ago
Aug 06, 2019
|
Bought
501 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 142656
|
3.51 USD |
|
5 years ago
Aug 06, 2019
|
Bought
501 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 142656
|
3.51 USD |
|
5 years ago
Aug 07, 2019
|
Bought
8.85 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 2500
|
3.54 USD |
|
5 years ago
Aug 06, 2019
|
Bought
17.9 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
3.575 USD |
|
5 years ago
Jul 23, 2019
|
Sell 211 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 39716
|
5.3161 USD |
|
5 years ago
Jul 24, 2019
|
Sell 267 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 53240
|
5.0096 USD |
|
5 years ago
Jul 25, 2019
|
Sell 5.6 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 1400000
|
4 USD |
|
5 years ago
Jul 01, 2019
|
Bought
232 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 59243
|
3.91 USD |
|
5 years ago
Jun 28, 2019
|
Bought
2.1 M USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 565178
|
3.72 USD |
|
5 years ago
Jun 27, 2019
|
Bought
110 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 32923
|
3.34 USD |
|
5 years ago
Jul 01, 2019
|
Bought
232 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 59243
|
3.91 USD |
|
5 years ago
Jun 28, 2019
|
Bought
2.1 M USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 565178
|
3.72 USD |
|
5 years ago
Jun 27, 2019
|
Bought
110 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 32923
|
3.34 USD |
|
5 years ago
Jun 14, 2019
|
Bought
39.7 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 11657
|
3.4028 USD |
|
5 years ago
Jun 13, 2019
|
Bought
1.21 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 343
|
3.52 USD |
|
5 years ago
Jun 11, 2019
|
Bought
22 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 6000
|
3.67 USD |
|
5 years ago
Jun 07, 2019
|
Bought
31 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 9212
|
3.3672 USD |
|
5 years ago
Jun 07, 2019
|
Bought
33.8 K USD
|
LEA LEIV
Chief Financial Officer
|
+ 10000
|
3.38 USD |
|
5 years ago
Jun 06, 2019
|
Bought
55.2 K USD
|
LEA LEIV
Chief Financial Officer
|
+ 15500
|
3.56 USD |
|
6 years ago
Dec 27, 2018
|
Bought
65.9 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 20000
|
3.2942 USD |
|
6 years ago
Dec 21, 2018
|
Bought
102 K USD
|
LEA LEIV
Chief Financial Officer
|
+ 24700
|
4.1461 USD |
|
6 years ago
Dec 20, 2018
|
Bought
22 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
4.39 USD |
|
6 years ago
Dec 20, 2018
|
Bought
22 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
4.4 USD |
|
6 years ago
Dec 06, 2018
|
Bought
29.9 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
5.9868 USD |
|
6 years ago
Dec 04, 2018
|
Bought
8.94 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 1502
|
5.95 USD |
|
6 years ago
Mar 12, 2018
|
Bought
5 M USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 588235
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
5 M USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 588235
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
10 M USD
|
Novo Holdings A/S
10 percent owner
|
+ 1176470
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
2.01 M USD
|
Gould Terry P
director, 10 percent owner:
|
+ 236128
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
1.08 M USD
|
Gould Terry P
director, 10 percent owner:
|
+ 126806
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
745 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 87668
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
594 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 69864
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
576 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 67769
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
2.01 M USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 236128
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
1.08 M USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 126806
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
745 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 87668
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
594 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 69864
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
576 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 67769
|
8.5 USD |
|
6 years ago
Mar 12, 2018
|
Bought
850 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 100000
|
8.5 USD |
|
7 years ago
Nov 20, 2017
|
Bought
108 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 10000
|
10.785 USD |
|
7 years ago
Jun 23, 2017
|
Bought
219 K USD
|
Novo Holdings A/S
10 percent owner
|
+ 20000
|
10.95 USD |
|
7 years ago
Jun 13, 2017
|
Bought
25.4 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 2500
|
10.14 USD |
|
7 years ago
Jun 13, 2017
|
Bought
24.4 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 2500
|
9.75 USD |
|
7 years ago
Jun 12, 2017
|
Bought
110 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 11216
|
9.8239 USD |
|
7 years ago
Jun 09, 2017
|
Bought
37.4 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 3784
|
9.89 USD |
|
7 years ago
Jun 09, 2017
|
Bought
49.8 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 5000
|
9.95 USD |
|
8 years ago
Jun 24, 2016
|
Bought
11.7 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 900
|
12.99 USD |
|
8 years ago
Jun 23, 2016
|
Bought
1.29 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 100
|
12.92 USD |
|
8 years ago
Jun 24, 2016
|
Bought
11.7 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 900
|
12.99 USD |
|
8 years ago
Jun 23, 2016
|
Bought
1.29 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 100
|
12.92 USD |
|
8 years ago
Jun 21, 2016
|
Bought
336 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 26083
|
12.87 USD |
|
8 years ago
Jun 17, 2016
|
Bought
154 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 12300
|
12.48 USD |
|
8 years ago
Jun 21, 2016
|
Bought
336 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 26083
|
12.87 USD |
|
8 years ago
Jun 17, 2016
|
Bought
154 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 12300
|
12.48 USD |
|
8 years ago
Jun 16, 2016
|
Bought
60.2 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 5000
|
12.04 USD |
|
8 years ago
Jun 15, 2016
|
Bought
59.7 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 5000
|
11.94 USD |
|
8 years ago
Jun 14, 2016
|
Bought
127 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 10000
|
12.71 USD |
|
8 years ago
Jun 16, 2016
|
Bought
60.2 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 5000
|
12.04 USD |
|
8 years ago
Jun 15, 2016
|
Bought
59.7 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 5000
|
11.94 USD |
|
8 years ago
Jun 14, 2016
|
Bought
127 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 10000
|
12.71 USD |
|
8 years ago
Jun 10, 2016
|
Bought
260 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 20000
|
12.98 USD |
|
8 years ago
Jun 09, 2016
|
Bought
388 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 30000
|
12.95 USD |
|
8 years ago
Jun 10, 2016
|
Bought
260 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 20000
|
12.98 USD |
|
8 years ago
Jun 09, 2016
|
Bought
388 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 30000
|
12.95 USD |
|
8 years ago
May 20, 2016
|
Bought
61.7 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 4716
|
13.09 USD |
|
8 years ago
May 20, 2016
|
Bought
61.7 K USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 4716
|
13.09 USD |
|
8 years ago
May 19, 2016
|
Bought
778 USD
|
ORBIMED ADVISORS LLC
Director
|
+ 61
|
12.75 USD |
|
8 years ago
May 19, 2016
|
Bought
30.7 K USD
|
ORBIMED ADVISORS LLC
Director
|
+ 2539
|
12.11 USD |
|
8 years ago
May 18, 2016
|
Bought
48.5 K USD
|
ORBIMED ADVISORS LLC
Director
|
+ 4200
|
11.55 USD |
|
8 years ago
May 19, 2016
|
Bought
778 USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 61
|
12.75 USD |
|
8 years ago
May 19, 2016
|
Bought
30.7 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 2539
|
12.11 USD |
|
8 years ago
May 18, 2016
|
Bought
48.5 K USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 4200
|
11.55 USD |
|
8 years ago
May 13, 2016
|
Bought
2.98 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 300
|
9.9367 USD |
|
8 years ago
May 12, 2016
|
Bought
300 K USD
|
MILLER RICHARD A MD
President and CEO
|
+ 30000
|
10 USD |
|
8 years ago
May 12, 2016
|
Bought
700 K USD
|
Novo A/S
10 percent owner
|
+ 70000
|
10 USD |
|
8 years ago
Mar 29, 2016
|
Bought
10 M USD
|
Novo A/S
10 percent owner
|
+ 666666
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
8.25 M USD
|
ORBIMED ADVISORS LLC
director, 10 percent owner:
|
+ 550000
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
8.25 M USD
|
Thompson Peter A.
director, 10 percent owner:
|
+ 550000
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
822 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 54777
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
799 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 53239
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
776 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 51712
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
604 K USD
|
ADAMS STREET PARTNERS LLC
10 percent owner
|
+ 40272
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
822 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 54777
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
799 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 53239
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
776 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 51712
|
15 USD |
|
8 years ago
Mar 29, 2016
|
Bought
604 K USD
|
Gould Terry P
director, 10 percent owner:
|
+ 40272
|
15 USD |
7. News
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders.
seekingalpha.com
- 1 month ago
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.
benzinga.com
- 1 month ago
Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday.
benzinga.com
- 1 month ago
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m.
globenewswire.com
- 1 month ago
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024
globenewswire.com
- 1 month ago
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal
globenewswire.com
- 1 month ago
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
zacks.com
- 2 months ago
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases
globenewswire.com
- 2 months ago
Corvus Pharmaceuticals: The Market Likes The Story
Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked of a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus or is some profit taking on the horizon?
seekingalpha.com
- 2 months ago
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Li Watsek - Cantor Jiale Song - Jefferies Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Jeff Jones - Oppenheimer Operator Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call. At this time participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m.
globenewswire.com
- 2 months ago
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract
globenewswire.com
- 2 months ago
8. Profile
Summary
Corvus Pharmaceuticals, Inc. CRVS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 322 M
Dividend Yield
0.00%
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Contact
863 Mitten Road, Burlingame, CA, 94010
https://www.corvuspharma.com
IPO
Date
March 23, 2016
Employees
28
Officers
Mr. Leiv Lea
Chief Financial Officer
Dr. William Benton Jones Ph.D.
Senior Vice President of Pharmaceutical Development
Mr. Jeffrey S. Arcara
Chief Business Officer
Dr. Richard A. Miller M.D.
Co-Founder, President, Chief Executive Officer & Chairman of the Board
Dr. Peter A. Thompson FACP, M.D.
Co-Founder & Independent Director
Dr. James T. Rosenbaum M.D.
Senior Vice President of Research